Investment Thesis
Boston Scientific demonstrates robust fundamental health with strong revenue growth of 19.9% YoY, healthy profitability margins (69% gross, 18% operating, 14.4% net), and excellent cash generation ($3.7B free cash flow). The company maintains solid financial leverage (0.46x debt/equity) with strong interest coverage (10.4x) and good liquidity (1.62x current ratio), supporting sustainable capital allocation and growth investments.
BSX Strengths
- Strong revenue growth of 19.9% YoY demonstrates market demand and successful business expansion in medical devices sector
- Excellent free cash flow generation of $3.7B (18.2% FCF margin) provides flexibility for dividends, debt reduction, and acquisitions
- Conservative balance sheet with 0.46x debt/equity ratio and 10.4x interest coverage indicates financial stability and low default risk
- Healthy profitability margins across all levels (69% gross, 18% operating, 14.4% net) showing pricing power and operational efficiency
- Strong current ratio of 1.62x and quick ratio of 1.08x provide adequate liquidity for near-term obligations
BSX Risks
- Net income growth of only 0.2% YoY despite 19.9% revenue growth suggests margin compression or elevated operating expenses requiring monitoring
- Significant long-term debt of $11.1B represents meaningful leverage that limits financial flexibility and requires consistent cash generation
- Medical device industry faces regulatory risks, competitive pressures, and potential pricing constraints from healthcare reforms
- 23 Form 4 insider filings warrant monitoring for insider sentiment changes, though volume alone does not indicate negative activity
Key Metrics to Watch
- Operating margin trend - monitor whether 18% level is sustainable or continuing to compress
- Free cash flow consistency - ensure $3.7B level is maintainable and growing with revenue
- Debt reduction progress - track whether company is using strong FCF to deleverage toward lower debt/equity ratios
- Revenue growth sustainability - validate whether 19.9% growth represents organic expansion or acquisition-driven
BSX Financial Metrics
Revenue
$20.1B
Net Income
$2.9B
EPS (Diluted)
$1.94
Free Cash Flow
$3.7B
Total Assets
$43.7B
Cash Position
$2.0B
BSX Profitability Ratios
Gross Margin
69.0%
Operating Margin
18.0%
Net Margin
14.4%
ROE
12.0%
ROA
6.6%
FCF Margin
18.2%
BSX Balance Sheet & Liquidity
Current Ratio
1.62x
Quick Ratio
1.08x
Debt/Equity
0.46x
Debt/Assets
0.0%
Interest Coverage
10.35x
Long-term Debt
$11.1B
Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: Mar 17, 2026 |
Data as of: 2025-12-31 |
Powered by Claude AI